Novartis wins US court appeal after challenge to Gilenya patent
This decision confirms the validity of the Gilenya patent and allows that injunction to remain in place, Novartis said04-01-2022
04-01-2022
NOVARTIS INDIA LTD. - 500672 - Board Meeting Intimation for Consideration Of The Unaudited Financial Results Of The Company For The Third Quarter Ending On December 31, 2021
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 ,inter alia, to consider and approve the Unaudited financial results of the Company for the third quarter ending on December 31, 2021 . Kindly take the same on record.31-12-2021
NOVARTIS INDIA LTD. - 500672 - Closure of Trading Window
Please be informed that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 10, 2022, to inter alia consider the Unaudited financial results of the Company for the third quarter ending on December 31, 2021 ("said results"). In this connection, further note that pursuant to the Company''s Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company shall remain closed from Saturday, January 1, 2022 to Saturday, February 12, 2022 (both days inclusive). The same is being duly communicated to all the Designated Persons under the Code which is available on the Company''s website i.e. www.novartis.in This is for your information.31-12-2021
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that we are issuing a duplicate share certificate to shareholder as detailed in the attachment, as per the information received from the Company's Registrar and Share Transfer Agent on December 22, 2021. Further, we wish to inform you that as per the information received from the Company's Registrar and Share Transfer Agent on December 29, 2021, shareholders have reported the loss of share certificates as detailed in the attachment. Request you to take the same on record as required under the provisions of the said Regulation.29-12-2021
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that we are issuing a duplicate share certificates to the shareholder as detailed in the attachment, as per the information received from the Company's Registrar and Share Transfer Agent on December 22, 2021. Request you to take the same on record as required under the provisions of the said Regulation.24-12-2021
Novartis to buy gene-therapy company targeting eye condition
Swiss healthcare giant to pay up to $1.5 billion for British biotech Gyroscope22-12-2021
NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr. Felix Doss has tendered his resignation from the position of Chief Financial Officer of the Company, to pursue opportunities outside of Novartis. The resignation has been accepted and he will be relieved from his responsibilities at the end of business hours on December 31, 2021. The Company is in the process of identifying a suitable successor and the same will be communicated to the stock exchange, once the position is filled up. Kindly take note of the above on record.20-12-2021
Novartis to buy back up to $15 billion of its shares
Novartis said it will use the proceeds from the recent sale of its stake in Roche Holding to buy back up to $15 billion of its shares by the end of 202316-12-2021
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that we are issuing a duplicate share certificate to the shareholder, as detailed in the attachment as per the information received from the Company's Registrar and Share Transfer Agent on December 10, 2021.14-12-2021
Novartis India Ltd - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that we are issuing a duplicate share certificate to the shareholder, as per the information received from the Company's Registrar and Share Transfer Agent on November 26, 2021 as detailed in the attachment.30-11-2021